Gamma1 heavy chain (1-454) [VH (Homo sapiens IGHV3-30-5*03 (95.9%) -(IGHD) -IGHJ6*01 (93.8%), CDR-IMGT [8.8.16] (27-34.52-59.98-113)) (1-124) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14 (CH1R120>K(221) (125-222), hinge 1-15 (223-237), CH2 (238-347), CH3 E12 (363), M14 (365), F85.2>F (pAMF) (411) (348-452), CHS (453-454)) (125-454)], (227-215')-disulfide with kappa light chain (1'-215') [V-KAPPA (Homo sapiens IGKV1-12*01 (92.6%) -IGKJ4*01 (100%), CDR-IMGT [6.3.9] (28'-33'.51'-53'.90'-98')) (1'-108') -Homo sapiens IGKC*01 (100%), Km3, A45.1 (154'), V101 (192') (109'-215')]; dimer (233-233'':236-236'')-bisdisulfide; produced by a cell-free protein expression system based on Escherichia coli lysate, non-glycosylated; substituted at C-4 of the L-phenylalanyl residues 411 and 411'' with {8-[(2S)-1-{[(1<sup>4</sup>S,1<sup>6</sup>S,2R,3<sup>2</sup>S,3<sup>3</sup>S,4S,10E,12E,14R)-8<sup>6</sup>-chloro-1<sup>4</sup>-hydroxy-8<sup>5</sup> ,14-dimethoxy-2,3<sup>3</sup>,7,10-tetramethyl-1<sup>2</sup> ,6-dioxo-7-aza-1(6,4)-[1,3]oxazinana-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-4-yl]oxy}-2,3,9-trimethyl-1,4,8,24-tetraoxo-12,15,18,21-tetraoxa-3,9,25-triazaoctacosan-28-oyl]-8,9-dihydro-1H(or 3H)- dibenzo[b,f][1,2,3]triazolo[4,5-d]azocin-1(or 3)-yl}methyl (debotansine) groups
Follicular Lymphoma
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 65/ 100
Competitive context
210 Active assets in the Follicular Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CYCLOSPORIN A Fred Hutchinson Cancer Center | Phase 2/3 | BBB |
Romidepsin City of Hope Medical Center | Phase 2 | BBB |
Busulphan Masonic Cancer Center, University of Minnesota | Phase 2/3 | BBB |
VINCRISTINE SULFATE National Cancer Institute (NCI) | Phase 3 | BBB |
Irinotecan University of Michigan Rogel Cancer Center | Phase 2 | BBB |
View all 50 →
Same molecule, other indications
Gamma1 heavy chain (1-454) [VH (Homo sapiens IGHV3-30-5*03 (95.9%) -(IGHD) -IGHJ6*01 (93.8%), CDR-IMGT [8.8.16] (27-34.52-59.98-113)) (1-124) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14 (CH1R120>K(221) (125-222), hinge 1-15 (223-237), CH2 (238-347), CH3 E12 (363), M14 (365), F85.2>F (pAMF) (411) (348-452), CHS (453-454)) (125-454)], (227-215')-disulfide with kappa light chain (1'-215') [V-KAPPA (Homo sapiens IGKV1-12*01 (92.6%) -IGKJ4*01 (100%), CDR-IMGT [6.3.9] (28'-33'.51'-53'.90'-98')) (1'-108') -Homo sapiens IGKC*01 (100%), Km3, A45.1 (154'), V101 (192') (109'-215')]; dimer (233-233'':236-236'')-bisdisulfide; produced by a cell-free protein expression system based on Escherichia coli lysate, non-glycosylated; substituted at C-4 of the L-phenylalanyl residues 411 and 411'' with {8-[(2S)-1-{[(1<sup>4</sup>S,1<sup>6</sup>S,2R,3<sup>2</sup>S,3<sup>3</sup>S,4S,10E,12E,14R)-8<sup>6</sup>-chloro-1<sup>4</sup>-hydroxy-8<sup>5</sup> ,14-dimethoxy-2,3<sup>3</sup>,7,10-tetramethyl-1<sup>2</sup> ,6-dioxo-7-aza-1(6,4)-[1,3]oxazinana-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-4-yl]oxy}-2,3,9-trimethyl-1,4,8,24-tetraoxo-12,15,18,21-tetraoxa-3,9,25-triazaoctacosan-28-oyl]-8,9-dihydro-1H(or 3H)- dibenzo[b,f][1,2,3]triazolo[4,5-d]azocin-1(or 3)-yl}methyl (debotansine) groups is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →